CD274 and hepatocellular carcinoma: The IMbrave150 phase III trial disclosed an improved median overall survival in patients with unresectable HCC from 13.4 months with therapy of sorafenib to 19.2 months when treated with the combinatory therapy of bevacizumab (anti-VEGF antibody) and atezolizumab (PD-L1 inhibitor) [118].